BG63606B1 - Модифицирани човешки сз протеини - Google Patents

Модифицирани човешки сз протеини Download PDF

Info

Publication number
BG63606B1
BG63606B1 BG101295A BG10129597A BG63606B1 BG 63606 B1 BG63606 B1 BG 63606B1 BG 101295 A BG101295 A BG 101295A BG 10129597 A BG10129597 A BG 10129597A BG 63606 B1 BG63606 B1 BG 63606B1
Authority
BG
Bulgaria
Prior art keywords
protein
factor
protein according
amino acid
convertase
Prior art date
Application number
BG101295A
Other languages
Bulgarian (bg)
English (en)
Other versions
BG101295A (en
Inventor
Richard Harrison
Timothy FARRIES
Original Assignee
Imutran Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9418147A external-priority patent/GB9418147D0/en
Priority claimed from GBGB9509102.1A external-priority patent/GB9509102D0/en
Application filed by Imutran Limited filed Critical Imutran Limited
Publication of BG101295A publication Critical patent/BG101295A/xx
Publication of BG63606B1 publication Critical patent/BG63606B1/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BG101295A 1994-09-08 1997-03-07 Модифицирани човешки сз протеини BG63606B1 (bg)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9418147A GB9418147D0 (en) 1994-09-08 1994-09-08 Modified proteins
GBGB9509102.1A GB9509102D0 (en) 1995-05-04 1995-05-04 Modified proteins
PCT/GB1995/002121 WO1996007738A2 (en) 1994-09-08 1995-09-08 Modified human c3 proteins

Publications (2)

Publication Number Publication Date
BG101295A BG101295A (en) 1997-12-30
BG63606B1 true BG63606B1 (bg) 2002-06-28

Family

ID=26305590

Family Applications (1)

Application Number Title Priority Date Filing Date
BG101295A BG63606B1 (bg) 1994-09-08 1997-03-07 Модифицирани човешки сз протеини

Country Status (21)

Country Link
US (1) US5849297A (zh)
EP (1) EP0779922B1 (zh)
JP (1) JPH10505241A (zh)
CN (1) CN1104501C (zh)
AT (1) ATE273388T1 (zh)
AU (1) AU707004B2 (zh)
BG (1) BG63606B1 (zh)
BR (1) BR9509172A (zh)
CA (1) CA2197888A1 (zh)
CZ (1) CZ290596B6 (zh)
DE (1) DE69533359T2 (zh)
ES (1) ES2224133T3 (zh)
FI (1) FI970979A (zh)
HU (1) HUT77874A (zh)
NO (1) NO971059L (zh)
NZ (2) NZ333949A (zh)
PL (1) PL319040A1 (zh)
RO (1) RO117189B1 (zh)
RU (1) RU2194713C2 (zh)
SK (1) SK29697A3 (zh)
WO (1) WO1996007738A2 (zh)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP9900789A3 (en) 1996-03-07 2001-10-29 Imutran Ltd Down-regulation resistant c3 convertase
EP0972200A1 (en) * 1997-03-06 2000-01-19 Bion Diagnostic Sciences, Inc. Screening and treatment using complement regulator or receptor proteins
US6221621B1 (en) 1997-03-06 2001-04-24 Bard Diagnostic Sciences, Inc. Methods of screening for colorectal cancers in which a complement Factor I or related protein is associated
WO2001092295A2 (en) * 2000-05-30 2001-12-06 University Of Toronto Ligands for cd21 and compositions thereof for modulating immune responses
US6756476B2 (en) * 2001-04-30 2004-06-29 Syn X Pharma, Inc. Biopolymer marker indicative of disease state having a molecular weight of 2021 daltons
US6998243B2 (en) * 2001-04-30 2006-02-14 Syn X Pharma, Inc. Biopolymer marker indicative of disease state having a molecular weight of 1793 daltons
US7314717B2 (en) * 2001-04-30 2008-01-01 Nanogen Inc. Biopolymer marker indicative of disease state having a molecular weight of 1562 daltons
US7294688B2 (en) * 2001-04-30 2007-11-13 Nanogen Inc. Biopolymer marker indicative of disease state having a molecular weight of 1348 daltons
US7179610B2 (en) * 2001-11-23 2007-02-20 Nanogen Inc. Complement C3 precursor biopolymer markers indicative of insulin resistance
US7097989B2 (en) * 2001-11-23 2006-08-29 Syn X Pharma, Inc. Complement C3 precursor biopolymer markers predictive of type II diabetes
WO2005107785A2 (en) * 2004-04-30 2005-11-17 University Of Hawaii Human complement c3 derivates with cobra venom factor-like function
US10206998B2 (en) 2005-01-12 2019-02-19 Proteonova, Inc. Modular targeted therapeutic agents and methods of making same
EP3431503A1 (en) * 2005-01-12 2019-01-23 Proteonova, Inc. Method for making targeted therapeutic agents
WO2010056399A1 (en) * 2008-11-17 2010-05-20 Incode Biopharmaceutics, Inc. Method and composition for modulating the immune system and various inflammatory conditions comprising complement depletors
RU2542401C1 (ru) * 2013-11-06 2015-02-20 Федеральное бюджетное учреждение науки "Московский научно-исследовательский институт эпидемиологии и микробиологии им. Г.Н. Габричевского" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека Способ определения функциональной активности компонента с2 комплемента человека
RU2542404C1 (ru) * 2013-11-06 2015-02-20 Федеральное бюджетное учреждение науки "Московский научно-исследовательский институт эпидемиологии и микробиологии им. Г.Н. Габричевского" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека Способ определения функциональной активности компонента с4 комплемента человека
US11903996B2 (en) * 2015-10-07 2024-02-20 David C. Fritzinger Modulators of complement function
CN113214373B (zh) * 2020-02-06 2022-08-30 深圳华大基因股份有限公司 新包虫病抗原Murinoglobulin-2蛋白
US11918624B2 (en) * 2020-06-10 2024-03-05 Kelsius Laboratories LLC Therapeutic composition for use in the treatment of COVID-19 and other cytokine storm associated disorders

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4661347A (en) * 1982-11-12 1987-04-28 Scripps Clinic Cytotoxic compositions

Also Published As

Publication number Publication date
FI970979A0 (fi) 1997-03-07
AU3477295A (en) 1996-03-27
BG101295A (en) 1997-12-30
AU707004B2 (en) 1999-07-01
CN1162335A (zh) 1997-10-15
NO971059L (no) 1997-05-07
FI970979A (fi) 1997-03-07
CN1104501C (zh) 2003-04-02
ATE273388T1 (de) 2004-08-15
WO1996007738A2 (en) 1996-03-14
ES2224133T3 (es) 2005-03-01
DE69533359T2 (de) 2005-07-28
RO117189B1 (ro) 2001-11-30
JPH10505241A (ja) 1998-05-26
CA2197888A1 (en) 1996-03-14
CZ68597A3 (en) 1997-11-12
NZ333949A (en) 2000-06-23
DE69533359D1 (de) 2004-09-16
EP0779922B1 (en) 2004-08-11
PL319040A1 (en) 1997-07-21
HUT77874A (hu) 1998-09-28
SK29697A3 (en) 1998-01-14
MX9701783A (es) 1997-10-31
US5849297A (en) 1998-12-15
WO1996007738A3 (en) 1996-03-28
CZ290596B6 (cs) 2002-08-14
RU2194713C2 (ru) 2002-12-20
BR9509172A (pt) 1997-11-25
NZ292565A (en) 1999-03-29
NO971059D0 (no) 1997-03-07
EP0779922A2 (en) 1997-06-25

Similar Documents

Publication Publication Date Title
BG63606B1 (bg) Модифицирани човешки сз протеини
JP6262721B2 (ja) 敗血症の予防用または治療用の組成物
EP3030252B1 (en) Compounds and methods for inhibiting phosphate transport
JP5913115B2 (ja) 胃腸障害のための処置
EP2987497B1 (en) Composition for treating and preventing ischemic damage
CN109310732A (zh) 用于阻止或减缓前列腺癌的进展的神经丝肽
US6221657B1 (en) Modified human C3 DNA sequences and vectors
AU726187B2 (en) Down-regulation resistant C3 convertase
Checler et al. [TRP11]-neurotensin and xenopsin discriminate between rat and guinea-pig neurotensin receptors
KR101576904B1 (ko) 파골세포 분화 및 활성 억제능을 갖는 펩타이드 및 이의 용도
WO1994018237A1 (en) Novel peptide having receptor activity and dna coding for said peptide
Ekhlasi-Hundrieser et al. Point mutations abolishing the mannose-binding capability of boar spermadhesin AQN-1
DE60120187T2 (de) Verkürztes bard1 protein und dessen diagnostische und therapeutische anwendungen
WO2004069857A2 (en) “peptides, compositions and uses thereof”
Rebollo et al. Peptides that inhibit binding between set and caspase-9
US7074889B2 (en) Identification of a new cytotoxic activity from the ink of Aplysia punctata
KR20160097244A (ko) 항산화 효과를 가지는 펩티드 및 이를 포함하는 조성물
KR101170215B1 (ko) 우성 음성 돌연변이 단백질 ｒ１４７ｅ 및 ｙ８１４ａ, 및 이들의 의학적 용도
KR20160126519A (ko) 발기부전 치료 활성을 가지는 펩티드 및 이를 포함하는 조성물
EP1943268A1 (en) Use of the gonadotropin-releasing hormone ii antagonists and its analogues
Bredesen et al. Novel Synthetic Hunter-Killer Peptides Target and Destroy Prostate Cancer
Seger Structural characterization and biological activities of the amino-terminal fragments of pro-opiomelanocortin
Nierengarten New approaches to generating semi-synthetic post-translationally modified proteins
MXPA97001783A (es) Proteinas c3 humanas modificadas